Amneal Pharmaceuticals, Inc. (AMRX) vs CG Oncology Inc. (CGON)
A side-by-side comparison of Amneal Pharmaceuticals, Inc. and CG Oncology Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMRX
Amneal Pharmaceuticals, Inc.
$20.05HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
CGON
CG Oncology Inc.
$64.74HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — AMRX vs CGON
growth of $100 · dividends reinvested · last 3yAMRX +272.0% (+55.0%/yr)CGON +84.9% (+22.7%/yr)AMRX compounded faster over this window
AMRX CGON
AMRX vs CGON: by the numbers
- •AMRX is the larger company ($6.40B vs $5.71B market cap).
- •AMRX is profitable (5.05% net margin) while CGON runs a net loss (-3602.68%).
Metrics side by side
Valuation
| Metric | AMRX | CGON |
|---|---|---|
| P/E ratio | 41.13 | N/A |
| Forward P/E | 19.58 | N/A |
| P/S ratio | 2.05 | 916.86 |
| P/B ratio | 193.88 | 5.55 |
| EV / EBITDA | 15.17 | N/A |
| FCF yield | 1.30% | N/A |
Profitability
| Metric | AMRX | CGON |
|---|---|---|
| Gross margin | 39.32% | -15.02% |
| Operating margin | 12.93% | -4722.13% |
| Net margin | 5.05% | -3602.68% |
| ROE | 476.51% | -21.80% |
| ROIC | 13.45% | -24.33% |
Growth (annualized)
| Metric | AMRX | CGON |
|---|---|---|
| Revenue CAGR (5Y) | 8.67% | N/A |
| EPS CAGR (5Y) | -17.72% | N/A |
| FCF CAGR (5Y) | -14.46% | N/A |
| Total return CAGR (5Y) | 30.25% | N/A |
Frequently asked
- Is AMRX or CGON more profitable?
- AMRX runs the higher net margin — AMRX at 5.05% versus CGON at -3602.68%.
Go deeper
Dig into the metrics
Amneal Pharmaceuticals P/E ratioAmneal Pharmaceuticals ROECG Oncology ROEAmneal Pharmaceuticals operating marginCG Oncology operating marginAmneal Pharmaceuticals revenue growthCG Oncology revenue growthAmneal Pharmaceuticals free cash flowCG Oncology free cash flow
Amneal Pharmaceuticals & CG Oncology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.